drug therapy

Summary

Top Publications

  1. pmc Which drugs cause preventable admissions to hospital? A systematic review
    R L Howard
    Nottingham Primary Care Research Partnership, Broxtowe and Hucknall PCT, Hucknall Health Centre, Nottingham, UK
    Br J Clin Pharmacol 63:136-47. 2007
  2. pmc National mass drug administration costs for lymphatic filariasis elimination
    Ann S Goldman
    Department of Epidemiology, The George Washington School of Public Health and Health Services, Washington, DC, United States of America
    PLoS Negl Trop Dis 1:e67. 2007
  3. ncbi Role of pharmacist counseling in preventing adverse drug events after hospitalization
    Jeffrey L Schnipper
    Brigham and Women s Faulkner Hospitalist Program, Division of General Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02120 1613, USA
    Arch Intern Med 166:565-71. 2006
  4. ncbi Transporters and drug therapy: implications for drug disposition and disease
    Richard H Ho
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Pharmacol Ther 78:260-77. 2005
  5. doi An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia
    Karri A Bauer
    Department of Pharmacy, The Ohio State University Medical Center, Columbus, Ohio 43210, USA
    Clin Infect Dis 51:1074-80. 2010
  6. pmc ChemProt-2.0: visual navigation in a disease chemical biology database
    Sonny Kim Kjærulff
    Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, 2800 Lyngby, Denmark
    Nucleic Acids Res 41:D464-9. 2013
  7. ncbi Nonspecific medication side effects and the nocebo phenomenon
    Arthur J Barsky
    Department of Psychiatry, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 287:622-7. 2002
  8. doi Adverse drug reaction-related hospitalisations: a population-based cohort study
    Cornelis S van der Hooft
    Pharmaco epidemiology Unit, Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands
    Pharmacoepidemiol Drug Saf 17:365-71. 2008
  9. pmc Evaluation of the quality of drug therapy among elderly patients in nursing homes
    Asa Bergman
    Apoteket AB, Goteborg, Sweden
    Scand J Prim Health Care 25:9-14. 2007
  10. pmc The value of inpatient pharmaceutical counselling to elderly patients prior to discharge
    S A Al-Rashed
    School of Pharmacy, University of Bradford, Bradford BD7 1DP, UK
    Br J Clin Pharmacol 54:657-64. 2002

Detail Information

Publications324 found, 100 shown here

  1. pmc Which drugs cause preventable admissions to hospital? A systematic review
    R L Howard
    Nottingham Primary Care Research Partnership, Broxtowe and Hucknall PCT, Hucknall Health Centre, Nottingham, UK
    Br J Clin Pharmacol 63:136-47. 2007
    ....
  2. pmc National mass drug administration costs for lymphatic filariasis elimination
    Ann S Goldman
    Department of Epidemiology, The George Washington School of Public Health and Health Services, Washington, DC, United States of America
    PLoS Negl Trop Dis 1:e67. 2007
    ..3 billion people at risk...
  3. ncbi Role of pharmacist counseling in preventing adverse drug events after hospitalization
    Jeffrey L Schnipper
    Brigham and Women s Faulkner Hospitalist Program, Division of General Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02120 1613, USA
    Arch Intern Med 166:565-71. 2006
    ..Our objectives were to identify drug-related problems during and after hospitalization and to determine the effect of patient counseling and follow-up by pharmacists on preventable ADEs...
  4. ncbi Transporters and drug therapy: implications for drug disposition and disease
    Richard H Ho
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Pharmacol Ther 78:260-77. 2005
    The efficacy of drug therapy results from the complex interplay of multiple processes that govern drug disposition and response...
  5. doi An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia
    Karri A Bauer
    Department of Pharmacy, The Ohio State University Medical Center, Columbus, Ohio 43210, USA
    Clin Infect Dis 51:1074-80. 2010
    ..07) and the mean hospital costs were $21,387 less (P = .02). rPCR allows rapid differentiation of S. aureus bacteremia, enabling timely, effective therapy and is associated with decreased length of stay and health care costs...
  6. pmc ChemProt-2.0: visual navigation in a disease chemical biology database
    Sonny Kim Kjærulff
    Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, 2800 Lyngby, Denmark
    Nucleic Acids Res 41:D464-9. 2013
    ..Filtering options were included in order to facilitate and to guide dynamic search of specific queries...
  7. ncbi Nonspecific medication side effects and the nocebo phenomenon
    Arthur J Barsky
    Department of Psychiatry, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 287:622-7. 2002
    ....
  8. doi Adverse drug reaction-related hospitalisations: a population-based cohort study
    Cornelis S van der Hooft
    Pharmaco epidemiology Unit, Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands
    Pharmacoepidemiol Drug Saf 17:365-71. 2008
    ..To evaluate the extent, characteristics and determinants of adverse drug reaction (ADR)-related hospitalisations on a population-based level in 2003...
  9. pmc Evaluation of the quality of drug therapy among elderly patients in nursing homes
    Asa Bergman
    Apoteket AB, Goteborg, Sweden
    Scand J Prim Health Care 25:9-14. 2007
    To evaluate drug therapy quality among elderly nursing home residents. Secondary aims were to compare quality in young and old elderly and to determine whether number of prescribers affected quality of drug therapy.
  10. pmc The value of inpatient pharmaceutical counselling to elderly patients prior to discharge
    S A Al-Rashed
    School of Pharmacy, University of Bradford, Bradford BD7 1DP, UK
    Br J Clin Pharmacol 54:657-64. 2002
    ..We have evaluated if these summaries, together with in-patient pharmaceutical counselling backed up with a simple medicine reminder card, may help with the delivery of seamless pharmaceutical care...
  11. ncbi Validity of diagnostic and drug data in standardized nursing home resident assessments: potential for geriatric pharmacoepidemiology. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology
    G Gambassi
    Istituto di Medicina Interna e Geriatria, Universita Cattolica del Sacro Cuore, Rome, Italy
    Med Care 36:167-79. 1998
    ..The authors sought to ascertain reliability and validity of diagnostic and drug data in a database obtained by merging the Minimum Data Set with detailed information on drugs consumed by each resident...
  12. ncbi Drug-related morbidity and mortality: updating the cost-of-illness model
    F R Ernst
    College of Pharmacy, University of Arizona, Tucson 85721 0207, USA
    J Am Pharm Assoc (Wash) 41:192-9. 2001
    ..6 billion for the annual cost of drug-related morbidity and mortality resulting from drug-related problems (DRPs) in the ambulatory setting in the United States to reflect current treatment patterns and costs...
  13. ncbi Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study
    Wayne Hening
    Department of Neurology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    Sleep Med 5:237-46. 2004
    ..To assess the frequency, impact, and medical response to the restless legs syndrome (RLS) in a large multi-national primary care population...
  14. doi Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia
    Heinz Ludwig
    Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Pavillion 23, Montleartstrasse 37, Vienna 1160, Austria
    J Clin Oncol 27:2838-47. 2009
    ....
  15. doi Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality
    V R Cornelius
    Drug Safety Research Unit, Blundell Lane, Southampton, UK
    Pharmacoepidemiol Drug Saf 18:1223-31. 2009
    ..Methods to systematically review adverse effects have not been fully developed. We aimed to assess the current methods and reporting used by such reviews...
  16. doi Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases
    Chaim M Bell
    Department of Health Policy, Management, and Evaluation, Keenan Research Centre in Li Ka Shing Knowledge Institute at St Michael s Hospital, Toronto, Ontario, Canada
    JAMA 306:840-7. 2011
    ..The intensive care unit (ICU) may pose an even greater risk because of the focus on acute events and the presence of multiple transitions in care...
  17. doi Should non-inferiority drug trials be banned altogether?
    Grace Wangge
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, PO Box 80082, 3508TB Utrecht, The Netherlands
    Drug Discov Today 18:601-4. 2013
    ....
  18. ncbi Incidence and preventability of adverse drug events among older persons in the ambulatory setting
    Jerry H Gurwitz
    Meyers Primary Care Institute and the University of Massachusetts Medical School, 630 Plantation St, Worcester, Mass 01605, USA
    JAMA 289:1107-16. 2003
    ..Adverse drug events, especially those that may be preventable, are among the most serious concerns about medication use in older persons cared for in the ambulatory clinical setting...
  19. ncbi The expression of aversion to medicines in general practice consultations
    Nicky Britten
    Institute of Clinical Education, Peninsula Medical School, Universities of Plymouth and Exeter, St Luke s Campus, Exeter, Devon EX1 2LU, England, UK
    Soc Sci Med 59:1495-503. 2004
    ..The results of this paper suggest that using aversion as an interactional resource might be the only safe way for patients to express their aversion without seeming to breach the social contract...
  20. ncbi Sample size recalculation using conditional power
    J S Denne
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, U S A
    Stat Med 20:2645-60. 2001
    ..We do this within the framework of a two-group error-spending sequential test, modified so as to prevent inflation of the type I error rate...
  21. pmc Frequency of adverse drug reactions in children: a prospective study
    Annie Pierre Jonville-Bera
    Department of Clinical Pharmacology and Regional Drug Monitoring Centre, University Hospital of Tours, 2 Boulevard Tonellé, 37044 Tours Cedex, France
    Br J Clin Pharmacol 53:207-10. 2002
    ..To assess the frequency of adverse drug reactions (ADRs) in children in France...
  22. ncbi Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer
    Charlotte C Sun
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Unit 440, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Support Care Cancer 13:219-27. 2005
    ..Selection of second- or third-line chemotherapy ultimately depends on patient preferences for different side effects. To better understand this process, we evaluated preferences and symptom distress in patients with ovarian cancer...
  23. ncbi 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
    Walter T Hughes
    St Jude Children s Research Hospital, Memphis, TN, 38105, USA
    Clin Infect Dis 34:730-51. 2002
  24. ncbi Measurement, correlates, and health outcomes of medication adherence among seniors
    Shelly A Vik
    Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Ann Pharmacother 38:303-12. 2004
    ..To provide a comprehensive review of the literature on the measurement, correlates, and health outcomes of medication adherence among community-dwelling older adults...
  25. pmc How to calculate the dose of chemotherapy
    Howard Gurney
    Department of Medical Oncology and Palliative Care, Westmead Hospital, Westmead 2145, Australia
    Br J Cancer 86:1297-302. 2002
    ....
  26. pmc Indicators for preventable drug related morbidity: application in primary care
    C J Morris
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL, UK
    Qual Saf Health Care 13:181-5. 2004
    ..To apply in practice a series of validated indicators for preventable drug related morbidity (PDRM)...
  27. pmc Views of older persons with multiple morbidities on competing outcomes and clinical decision-making
    Terri R Fried
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    J Am Geriatr Soc 56:1839-44. 2008
    ....
  28. ncbi Preventable drug-related hospital admissions
    Almut G Winterstein
    Department of Pharmacy Health Care Administration, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Ann Pharmacother 36:1238-48. 2002
    ..To estimate the prevalence of preventable drug-related hospital admissions (PDRAs) and to explore if selected study characteristics affect prevalence estimates...
  29. ncbi The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients
    Antje Neubert
    Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    Drug Saf 27:1059-67. 2004
    ..This study investigates, for the first time in a German patient population, the impact of unlicensed and off-label drug use on ADRs in paediatric patients...
  30. pmc Finding multiple target optimal intervention in disease-related molecular network
    Kun Yang
    Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, China
    Mol Syst Biol 4:228. 2008
    ..A number of promising MTOI solutions were found to be both effective and safer...
  31. doi Defining rewardable innovation in drug therapy
    Jeffrey K Aronson
    Department of Primary Health Care, University of Oxford, 23 38 Hythe Bridge Street, Oxford OX1 2ET, UK
    Nat Rev Drug Discov 11:253-4. 2012
    ..Here, we propose a definition of innovation with respect to medicinal products, accompanied by a ranking of the importance of different types of innovativeness, with the aim of providing a basis for rewarding such innovation...
  32. ncbi Oral manifestations of drug therapy
    James Guggenheimer
    Departments of Oral Medicine, Pathology, and Otolaryngology, University of Pittsburgh School of Dental Medicine, 3501 Terrace Street, G 137 Salk, Pittsburgh, PA 15261, USA
    Dent Clin North Am 46:857-68. 2002
    ..The dental practitioner is often the primary health care provider who can recognize, diagnose, treat, and/or prevent these conditions...
  33. ncbi A pharmacist model of perceived responsibility for drug therapy outcomes
    Lourdes G Planas
    Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, P O Box 26901, Oklahoma City, OK 73190, USA
    Soc Sci Med 60:2393-403. 2005
    ..to reduce drug-related morbidity and to optimize patient outcomes by identifying, resolving, and preventing drug therapy problems...
  34. ncbi Inappropriate medication prescribing for the elderly by office-based physicians
    R R Aparasu
    College of Pharmacy, South Dakota State University, Brookings 57007 USA
    Ann Pharmacother 31:823-9. 1997
    ..To estimate the prevalence of inappropriate medications prescribed by office-based physicians for patients 65 years or older...
  35. ncbi Drug therapy in the elderly: improving quality and access
    Steven R Simon
    Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA, USA
    Clin Pharmacol Ther 73:387-93. 2003
  36. pmc Identifying systematic reviews of the adverse effects of health care interventions
    Su Golder
    Centre for Reviews and Dissemination CRD, University of York, York, YO10 5DD, UK
    BMC Med Res Methodol 6:22. 2006
    ..In order to carry out a methodological research survey of systematic reviews of adverse effects we needed to retrieve a sample of systematic reviews in which the primary outcome is an adverse effect or effects...
  37. doi Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era
    Mladen Tzvetkov
    Department of Clinical Pharmacology, University Medical Center, Gottingen, Germany
    Pathology 44:166-80. 2012
    ..We discuss here the challenges associated with choosing the correct therapy for patients who present to their physicians with personal genome data...
  38. doi Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy
    Leah Church Sera
    Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
    Clin Geriatr Med 28:273-86. 2012
    ..Consideration of initial dose adjustment, along with frequent medication reconciliation and analysis of the medication list, are keys to providing optimal pharmaceutical care for elderly patients...
  39. pmc Drug therapy in dental practice: nonopioid and opioid analgesics
    Daniel E Becker
    Sinclair Community College, Dayton, Ohio, USA
    Anesth Prog 52:140-9. 2005
    ..The clinician can and should develop a variety of effective, safe analgesic regimens, based on estimates of anticipated pain intensity that use sound pharmacological principles...
  40. ncbi Clinical pharmacy, pharmaceutical care, and the quality of drug therapy
    Charles D Hepler
    Department of Pharmacy Health Care Administration, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Pharmacotherapy 24:1491-8. 2004
    Because of concerns about patient safety and the quality of health care in America, in particular about drug therapy, pharmacists have unprecedented opportunities to increase their value and significance...
  41. ncbi Pharmacy data in epidemiological studies: an easy to obtain and reliable tool
    Taco B M Monster
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, Groningen, The Netherlands
    Pharmacoepidemiol Drug Saf 11:379-84. 2002
    ..However, most investigations on this subject studied selected populations or subsets. We studied the coverage of Dutch pharmacy data for our study cohort, and the agreement between the different sources...
  42. ncbi Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial
    Maria Crotty
    Flinders University Department of Rehabilitation and Aged Care, Repatriation General Hospital, Daw Park, South Australia
    Am J Geriatr Pharmacother 2:257-64. 2004
    ..Poorly executed transfers of older patients from hospitals to long-term care facilities carry the risk of fragmentation of care, poor clinical outcomes, inappropriate use of emergency department services, and hospital readmission...
  43. pmc Just what the doctor ordered. Review of the evidence of the impact of computerized physician order entry system on medication errors
    Tatyana A Shamliyan
    Division of Health Policy and Management, University of Minnesota School of Public Health, MMC 729, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Health Serv Res 43:32-53. 2008
    ..Of 252 identified in the search, 12 (4.8 percent) original investigations that compared rates of prescribing medication errors with handwritten and computerized physician orders were included...
  44. pmc Comparison of drug adherence rates among patients with seven different medical conditions
    Becky A Briesacher
    Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester, Massachusetts Meyers Primary Care Institute, Worcester, MA 01605, USA
    Pharmacotherapy 28:437-43. 2008
    ..To compare drug adherence rates among patients with gout, hypercholesterolemia, hypertension, hypothyroidism, osteoporosis, seizure disorders, and type 2 diabetes mellitus by using a standardized approach...
  45. ncbi Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting
    Jean Geber
    Department of Veterans Affairs Outpatient Clinic, Orlando, Florida, USA
    Pharmacotherapy 22:738-47. 2002
    ....
  46. ncbi Pharmacogenetics: potential for individualized drug therapy through genetics
    Julie A Johnson
    Department of Pharmacy Practice, Department of Pharmaceutics and Department of Medicine, University of Florida, Box 100486, Gainesville, FL 32610 0486, USA
    Trends Genet 19:660-6. 2003
  47. ncbi Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy
    G D Szklarz
    Department of Basic Pharmaceutical Sciences, West Virginia University, USA
    Drug Metab Dispos 26:1179-84. 1998
    ....
  48. pmc Selling sickness: the pharmaceutical industry and disease mongering
    Ray Moynihan
    Australian Financial Review, GPO Box 506, Sydney, 2201, Australia
    BMJ 324:886-91. 2002
  49. pmc Risk perception in drug therapy
    J K Aronson
    Br J Clin Pharmacol 62:135-7. 2006
  50. ncbi Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead
    Daniel W Nebert
    Division of Human Genetics, Department of Pediatrics and Molecular Developmental Biology, University of Cincinnati Medical Center, P O Box 670056, Cincinnati OH 45267 0056, USA
    Eur J Pharmacol 500:267-80. 2004
    ..reviews on this topic have painted an overly optimistic picture-suggesting that the advent of individualized drug therapy used by the practicing physician is fast approaching...
  51. doi Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy
    Guillermo Gervasini
    Department of Medical and Surgical Therapeutics, Division of Clinical Pharmacology, Medical School, University of Extremadura, 06071 Badajoz, Spain
    Eur J Clin Pharmacol 66:755-74. 2010
    ..Third, the use of a pharmacogenetic test as a standard of care for drug therapy has to overcome significant scientific, economic, commercial, political and educational barriers, among others, ..
  52. ncbi The effects of radiotherapy and chemotherapy on female reproduction
    D Meirow
    Department of Obstetrics and Gynecology, Rabin Medical Center, Israel
    Hum Reprod Update 7:535-43. 2001
    ..Increased knowledge of these mechanisms could help to identify potential effective inhibitors that can block the path of primordial follicles destruction and reduce ovarian failure rate...
  53. ncbi Use of cardiovascular drugs after acute myocardial infarction: a marked shift towards evidence-based drug therapy
    Asmund Reikvam
    Department of Pharmacotherapeutics, Faculty of Medicine, University of Oslo, N 0316 Oslo, Norway
    Cardiovasc Drugs Ther 16:451-6. 2002
    ....
  54. pmc Medication use by persons with chronic fatigue syndrome: results of a randomized telephone survey in Wichita, Kansas
    James F Jones
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Mail Stop A15, Atlanta, GA 30333, USA
    Health Qual Life Outcomes 1:74. 2003
    ..The objective of this study was to describe utilization of medications and supplements by persons with CFS and non-fatigued individuals representative of the general population of Wichita, Kansas...
  55. ncbi Principles of drug therapy for the elderly patient
    Rubin Bressler
    Department of Medicine, Sarver Heart Center, University of Arizona, Tucson, Ariz, USA
    Mayo Clin Proc 78:1564-77. 2003
    ....
  56. ncbi Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly
    Kenneth E Schmader
    Veterans Affairs Medical Center, Durham, North Carolina, USA
    Am J Med 116:394-401. 2004
    ..To determine if inpatient or outpatient geriatric evaluation and management, as compared with usual care, reduces adverse drug reactions and suboptimal prescribing in frail elderly patients...
  57. pmc A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals
    Michael J Dooley
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australian
    Br J Clin Pharmacol 57:513-21. 2004
    To determine the cost savings of pharmacist initiated changes to hospitalized patients' drug therapy or management in eight major acute care government funded teaching hospitals in Australia.
  58. ncbi [Drug utilization in adults: prevalence and individuals determinants]
    Andrea D Bertoldi
    Programa de Pós Graduação em Epidemiologia, Faculdade de Medicina, Universidade Federal de Pelotas, Pelotas, RS, Brasil
    Rev Saude Publica 38:228-38. 2004
    ..To study epidemiological patterns of drug utilization and its individual determinants and to classify drugs used into pharmacological groups...
  59. ncbi Aging biology and geriatric clinical pharmacology
    Allan J McLean
    Director, National Ageing Research Institute, P O Box 31, Parkville, VIC Australia
    Pharmacol Rev 56:163-84. 2004
    ..Even so, therapeutic advances generally may convert healthy longevity from an asset of fortunate individuals into a general social benefit...
  60. ncbi The role of cost-effectiveness analysis in the era of pharmacogenomics
    Christopher R Flowers
    Pharmaceutical Outcomes Research and Policy Program, University of Washington Medical Center, Seattle, Washington, USA
    Pharmacoeconomics 22:481-93. 2004
    ....
  61. ncbi Drug use patterns in young German women and association with mental disorders
    Isabel Hach
    Institute of Clinical Pharmacology, TU Dresden, Germany
    Ann Pharmacother 38:1529-34. 2004
    ..There is a lack of data about drug use patterns in young women. Mental disorders may influence those drug use patterns...
  62. pmc Assessing the benefit-harm balance at the bedside
    Yoon Kong Loke
    School of Medicine, Health Policy and Practice University of East Anglia, Norwich NR4 7TJ
    BMJ 329:7-8. 2004
  63. pmc Algorithms for optimizing drug therapy
    Peter Wanger
    Department of Clinical Neuroscience, Karolinska Institutet, St Erik s Eye Hospital S 112 82 Stockholm, Sweden
    BMC Med Inform Decis Mak 4:10. 2004
    b>Drug therapy has become increasingly efficient, with more drugs available for treatment of an ever-growing number of conditions...
  64. ncbi Inappropriate prescribing for elderly Americans in a large outpatient population
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 164:1621-5. 2004
    ..We sought to determine the extent of potentially inappropriate outpatient prescribing for elderly patients, as defined by the Beers revised list of drugs to be avoided in elderly populations...
  65. ncbi Can an algorithm for appropriate prescribing predict adverse drug events?
    Kimberly J Rask
    Department of Health Policy and Management, Rollins School of Public Health, Emory University School of Medicine, Atlanta, GA 30322, USA
    Am J Manag Care 11:145-51. 2005
    ..To evaluate whether a medication-appropriateness algorithm applied to pharmacy claims data can identify ambulatory patients at risk for experiencing adverse drug events (ADEs) from those medications...
  66. pmc Case reports of suspected adverse drug reactions--systematic literature survey of follow-up
    Yoon Kong Loke
    School of Medicine, Health Policy, and Practice, University of East Anglia, Norwich NR4 7TJ
    BMJ 332:335-9. 2006
    ..To determine whether anecdotal reports of suspected adverse drug reactions are valuable early warning signals...
  67. ncbi An observational study of changes to long-term medication after admission to an intensive care unit
    A J Campbell
    Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK
    Anaesthesia 61:1087-92. 2006
    ..Twenty-eight were continued beyond hospital discharge, some without apparent ongoing indication. Reliable mechanisms to prevent prescription errors are required...
  68. ncbi Drug-related hospitalizations in a tertiary care internal medicine service of a Canadian hospital: a prospective study
    Leslie Jo Samoy
    Clinical Service Unit Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, British Columbia, Canada
    Pharmacotherapy 26:1578-86. 2006
    ..To determine the frequency, severity, preventability, and classification of adverse drug events resulting in hospitalization, and to identify any patient, prescriber, drug, and system factors associated with these events...
  69. ncbi [A population-based study on use of medication by the elderly in Greater Metropolitan Belo Horizonte, Minas Gerais, Brazil]
    Antônio I de Loyola Filho
    Núcleo de Estudos em Saúde Pública e Envelhecimento, Centro de Pesquisas Rene Rachou, Fundacao Oswaldo Cruz, Brasil
    Cad Saude Publica 22:2657-67. 2006
    ....
  70. ncbi 99mTc-HYNIC Annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy
    S Rottey
    Division of Medical Oncology, University Hospital Ghent, Ghent, Belgium
    Q J Nucl Med Mol Imaging 51:182-8. 2007
    ..The aim of this study was to report on the relationship between preradiotherapy and prechemotherapy 99mTc-HYNIC Annexin-V tumor uptake values, reflecting ongoing apoptosis, and outcome to radiotherapy and/or chemotherapy...
  71. ncbi Individualized drug therapy
    Ann K Daly
    School of Clinical and Laboratory Sciences, Newcastle University Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
    Curr Opin Drug Discov Devel 10:29-36. 2007
    ..The introduction of pharmacogenetic tests into routine healthcare requires both a demonstration of cost-effectiveness and the availability of appropriate accessible testing systems...
  72. ncbi Hypnotic taper with or without self-help treatment of insomnia: a randomized clinical trial
    Geneviève Belleville
    Departement de Psychologie, Universite du Quebec a Montreal, Montreal, Quebec, Canada
    J Consult Clin Psychol 75:325-35. 2007
    ..The addition of a self-help treatment focusing on insomnia, a readily available and cost-effective alternative to individual psychotherapy, produced greater sleep improvement...
  73. pmc Automated acquisition of disease drug knowledge from biomedical and clinical documents: an initial study
    Elizabeth S Chen
    Clinical Informatics Research and Development, Partners HealthCare System, 93 Worcester Street, PO Box 81902, Wellesley, MA 02481, USA
    J Am Med Inform Assoc 15:87-98. 2008
    ..Explore the automated acquisition of knowledge in biomedical and clinical documents using text mining and statistical techniques to identify disease-drug associations...
  74. ncbi Oral drug therapy for multiple neglected tropical diseases: a systematic review
    Madhuri Reddy
    Department of Medicine, Hebrew Rehabilitation Center, Boston, Massachusetts 02131, USA
    JAMA 298:1911-24. 2007
    ..Seven of the most prevalent diseases have existing oral drug treatments. Identifying treatments that are effective against more than 1 disease could facilitate efficient and inexpensive treatment...
  75. pmc Clinical review: medication errors in critical care
    Eric Moyen
    Department of Critical Care Medicine, University of Calgary, Foothills Medical Centre, EG23A, 1403 29 Street NW, Calgary, AB, Canada
    Crit Care 12:208. 2008
    ..The aim of this article is to provide a basic review of medication errors in the ICU, identify risk factors for medication errors, and suggest strategies to prevent errors and manage their consequences...
  76. ncbi Education in clinical pharmacology at the Rijeka School of Medicine, Croatia
    V Vlahovic Palcevski
    Department of Pharmacology, University of Rijeka, Rijeka School of Medicine, Croatia
    Eur J Clin Pharmacol 54:685-9. 1998
    ..Education is the key to improved effectiveness and safety in drug therapy. Development of clinical pharmacology (CP) as an independent discipline at the Rijeka School of Medicine has ..
  77. pmc What is the quality of drug therapy clinical practice guidelines in Canada?
    I D Graham
    Departments of Medicine and of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ont
    CMAJ 165:157-63. 2001
    ..This study was designed to identify and describe guidelines in the database that make recommendations related to the use of drug therapy, and to assess their quality using a standardized guideline appraisal instrument.
  78. pmc Genetic variations in human G protein-coupled receptors: implications for drug therapy
    W Sadee
    Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco CA 94143 0446, USA
    AAPS PharmSci 3:E22. 2001
    Numerous genes encode G protein-coupled receptors (GPCRs)-a main molecular target for drug therapy. Estimates indicate that the human genome contains approximately 600 GPCR genes...
  79. ncbi Geriatric drug therapy and healthcare utilization in the United kingdom
    Anita Kennerfalk
    Department of Epidemiology, AstraZeneca R and D, S 431 83 Molndal, Sweden
    Ann Pharmacother 36:797-803. 2002
    To describe the use of prescription drug therapy, especially polypharmacy, in an elderly general population; to relate that use to age, gender, and different types of healthcare utilization; and to investigate the influence of selection ..
  80. ncbi Principles of drug therapy in older patients: rational drug prescribing
    Rebecca J Beyth
    Division of Health Services Research, Baylor College of Medicine, Houston Center for Quality of Care and Utilization Studies, Houston VAMC, Division of Health Services Research, Houston, TX 77030, USA
    Clin Geriatr Med 18:577-92. 2002
    ..Careful, compassionate attention to these factors can have a profound effect on improving the quality of life, medication use, and the overall cost of health care in this vulnerable population...
  81. ncbi Frequency and predictors of drug therapy interruptions after hospital discharge under physician drug budgets in Germany
    K Taxis
    Pharmazeutische Biologie, Pharmazeutisches Institut, Universitat Tubingen, Germany
    Int J Clin Pharmacol Ther 41:77-82. 2003
    We sought to study how frequently prescription drug therapy at hospital discharge was discontinued or changed by general practitioners under physician drug budgets in Germany and explore reasons and predictors for such discontinuations.
  82. ncbi Collaborative drug therapy management by pharmacists--2003
    Raymond W Hammond
    2001 2002 ACCP Task Force on Collaborative Drug Therapy Management, USA
    Pharmacotherapy 23:1210-25. 2003
    ..care community at large have come to better appreciate the growing complexity of providing effective and safe drug therapy in today's health care environment...
  83. ncbi Molecular characterization of a purified 5-HT4 receptor: a structural basis for drug efficacy
    Jean Louis Baneres
    UMR CNRS 5074, Chimie Biomoléculaire et Interactions Biologiques, Faculte de Pharmacie, 15 Avenue Ch Flahault, 34093 Montpellier Cedex 05, France
    J Biol Chem 280:20253-60. 2005
    ....
  84. ncbi Drug-drug interactions among recently hospitalised patients--frequent but mostly clinically insignificant
    Bente Glintborg
    Clinic of Internal Medicine I, H S Bispebjerg Hospital, 2100, Copenhagen, Denmark
    Eur J Clin Pharmacol 61:675-81. 2005
    ..The aim of the present study was to identify potential drug-drug interactions between drugs used by patients recently discharged from the hospital and, subsequently, to estimate the clinical implications of these interactions...
  85. ncbi Adherence to medication
    Lars Osterberg
    General Medicine Division, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    N Engl J Med 353:487-97. 2005
  86. ncbi The Critical Care Safety Study: The incidence and nature of adverse events and serious medical errors in intensive care
    Jeffrey M Rothschild
    Divisions of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Crit Care Med 33:1694-700. 2005
    ..We sought to study the incidence and nature of adverse events and serious errors in the critical care setting...
  87. ncbi Factors associated with potentially inappropriate drug utilization in a sample of rural community-dwelling older adults
    Susan J Blalock
    School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599 7360, USA
    Am J Geriatr Pharmacother 3:168-79. 2005
    ..The Beers criteria are often used to identify such medications. Past research has documented that use of Beers drugs is common among older adults...
  88. ncbi Implications of pharmacogenomics for drug development and clinical practice
    Geoffrey S Ginsburg
    Department of Medicine, School of Medicine, Center for Genomic Medicine, Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    Arch Intern Med 165:2331-6. 2005
    ..Although the potential of these technologies is driving change in the development of clinical sciences, it remains to be seen which health care systems level needs will be addressed...
  89. ncbi Impact of prescription-term deregulation with revised medical service fees on drug therapy management
    Hitoshi Kawazoe
    Department of Pharmacy, Kagawa University Hospital, 1750 1 Ikenobe, Miki cho, Kita gun, Kagawa 761 0793, Japan
    Yakugaku Zasshi 125:959-69. 2005
    ..There is a concern that the prescription-term deregulation could cause careless drug therapy management in order to extend the interval between patient hospital visits...
  90. ncbi Choice of delta: requirements and reality--results of a systematic review
    S Lange
    Institute for Quality and Efficiency in Health Care, Cologne, Germany
    Biom J 47:12-27; discussion 99-107. 2005
    ..Overall, it seems that a more global definition of 'irrelevance' might be warranted...
  91. ncbi A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials
    H M James Hung
    Division of Biometrics I, Office of Biostatistics, OPaSS, CDER, FDA, HFD 710, Room 5062, WOC2, 1451 Rockville Pike, Rockville, MD 20852, USA
    Biom J 47:28-36; discussion 99-107. 2005
    ..The margin can be a fixed margin or a margin functionally defined. Between-trial differences always exist and need to be properly considered...
  92. ncbi Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands
    Cornelis S van der Hooft
    Pharmaco epidemiology Unit, Department of Epidemiology and Biostatistics, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Drug Saf 29:161-8. 2006
    ..The incidence of adverse drug reaction (ADR)-related hospitalisations has usually been assessed within hospitals. Because of the variability in results and methodology, it is difficult to extrapolate these results to a national level...
  93. ncbi Cancer therapy-associated CNS neuropathology: an update and review of the literature
    Arie Perry
    Division of Neuropathology, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Acta Neuropathol 111:197-212. 2006
    ..Therefore, it is critical to recognize the full spectrum of cancer therapy-associated neuropathology, the topic of the current review...
  94. ncbi Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial
    Stephen Bent
    University of California and San Francisco Veterans Administration Medical Center, San Francisco, California 94121, USA
    Ann Intern Med 144:257-61. 2006
    ..There is no standard method of identifying adverse events in clinical trials...
  95. ncbi Reconciliation of medications
    Nancy M Saufl
    Preadmission Testing Center, Florida Hospital, Memorial Division, Ormond Beach, FL 32174, USA
    J Perianesth Nurs 21:126-7. 2006
  96. ncbi Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, California 94143 0350, USA
    Neurosurg Focus 20:E4. 2006
    ..In this paper the authors outline standard therapies and review the emerging role of targeted drug therapy in the treatment of recurrent GBM.
  97. pmc A meta-analysis of the association between adherence to drug therapy and mortality
    Scot H Simpson
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada T6G 2N8
    BMJ 333:15. 2006
    To evaluate the relation between adherence to drug therapy, including placebo, and mortality.
  98. ncbi Represcription after adverse drug reaction in the elderly: a descriptive study
    Carolien M J van der Linden
    Arch Intern Med 166:1666-7. 2006
  99. ncbi Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics
    Daniel W Nebert
    Division of Human Genetics, Department of Pediatrics and Molecular Developmental Biology, Center for Environmental Genetics, University of Cincinnati Medical Center, Cincinnati, OH 45267 0056, USA
    Trends Pharmacol Sci 27:580-6. 2006
    ..by themselves, either transcriptomics or proteomics will be particularly helpful in achieving individualized drug therapy. However, recent advances in metabonomics are exciting and show promise...
  100. ncbi Hypoxia, drug therapy and toxicity
    KangAe Lee
    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA
    Pharmacol Ther 113:229-46. 2007
    ..This review will summarize our current understanding of hypoxia signaling as it applies to drug therapy and toxicity and describe how these processes can influence the HIF-mediated balance between adaptation and ..
  101. ncbi Interventions of hospital pharmacists in improving drug therapy in children: a systematic literature review
    Navneet Sanghera
    The School of Pharmacy, Centre for Paediatric Pharmacy Research, Institute of Child Health, University of London, Great Ormond Street Hospital for Children, London, England
    Drug Saf 29:1031-47. 2006
    ..Age-specific changes in pharmacokinetics and pharmacodynamics further complicate drug therapy in children...

Research Grants81

  1. Hypertension Pharmacogenetics
    Julie Johnson; Fiscal Year: 2006
    ..Pharmacogenetics might significantly improve BP control and outcomes, as genetically-guided drug therapy selection could dramatically increase the number of patients who receive the best drug for their HTN...
  2. Understanding/ Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
    Eva Szigethy; Fiscal Year: 2009
    ..abstract_text> ..
  3. Principles of Therapy in Cerebellar Disease: Explorations in Ion Channel Mutants
    JOHN SAMUEL STAHL; Fiscal Year: 2013
    ..are affected early in many cerebellar disorders and thus a particularly promising and important target for a drug therapy;3) we can build upon the research that has already been done on the cause and treatment of eye movement ..
  4. A Hybrid PARP Inhibitor and Redox Catalyst for Lung Transplantation
    GARRY JOHN SOUTHAN; Fiscal Year: 2012
    ..A sham animal will not undergo ischemia nor receive drug therapy. We expect that R-503 will exhibit superior efficacy, relative to treatment with INO-1001, DHL, and their ..
  5. Genetics and Haloperidol Response
    Robert J Hitzemann; Fiscal Year: 2012
    ..by typical neuroleptic agents, it should be possible to develop an more effective regimen of antipsychotic drug therapy. Despite the introduction of the atypical antipsychotic drugs, there has been little to challenge this basic ..
  6. Combination drug treatment to inhibit multiple cell death pathways after TBI
    ALAN IRA FADEN; Fiscal Year: 2010
    ..death and improved functional recovery after moderate CCI injury in mice;3) to determine whether combined multi-drug therapy with the best HSP-70 inducer and best PARP-1 inhibitor, at optimal doses, has additive or synergistic effects ..
  7. Hybrid Katp Channel Opener and Redox Catalyst for Lung Transplantation
    Prakash Jagtap; Fiscal Year: 2013
    ..A sham rat undergoes thoracotomy but neither ischemia nor drug therapy. R-801 is expected to exhibit superior efficacy, relative to treatment with pinacidil, HMP, and their ..
  8. Drug Interactions at the Human Blood-Brain Barrier
    Jashvant D Unadkat; Fiscal Year: 2010
    ..In addition, our studies will measure the magnitude of such interactions. The results of our study should lead to better management of drug therapy and improvement of the drug development process.
  9. Improved Adventitial Sirolimus Therapy for Peripheral Artery Restenosis
    KIRK SEWARD; Fiscal Year: 2010
    ..The innovative product that will be developed in this proposal is a combination device/drug therapy that will be broadly applicable to vascular disease...
  10. ANALYSIS OF TRYPANOSOME MRNA SYNTHESIS BY GENE TRANSFER
    Vivian Bellofatto; Fiscal Year: 2010
    ..diverse mechanisms by which eukaryotes accomplish fundamentally similar ends, as well as potential targets for drug therapy against what remains a wide-spread and crippling pathogen...
  11. The Role of Alcohol in HIV Therapy Hepatotoxicity
    Craig J McClain; Fiscal Year: 2012
    ..The long-term goals of this study are to: (1) define mechanisms of hepatotoxicity induced by a combination of drug therapy and alcohol abuse in HIV patients and (2) discover potential therapeutic interventions for HAART hepatotoxicity,..
  12. Graves'Disease Therapy Risks to Mother and Fetus
    Scott A Rivkees; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: The goal of these studies is to determine the risks of antithyroid drug therapy during pregnancy on mother and fetus...
  13. Mahalia S Desruisseaux; Fiscal Year: 2015
    ..Thus, vascular compromise and alterations in Akt and tau may be important in the pathogenesis of malaria and may provide rational targets of drug therapy to ameliorate the consequences of this infection.
  14. Robert Harris; Fiscal Year: 2015
    ..will set the stage for the next level of studies that could culminate in a new form of gene-directe enzyme pro-drug therapy for colorectal cancer...
  15. John K Buolamwini; Fiscal Year: 2015
    ..approaches to preempt or treat mitochondrial toxicity will be an important advance in the field of nucleoside drug therapy. NRTI triphosphates, the metabolites that inhibit Pol g can be synthesized inside mitochondria from imported ..
  16. Barbara J Meyer; Fiscal Year: 2016
    ..the genetic pathways in which NHRs function will provide an opportunity to discover other gene targets for drug therapy, which might be applicable to humans...
  17. Mechanisms for the Effects of Hypothalamic PTP1B on Energy Balance
    KARYN JOANNE CATALANO; Fiscal Year: 2010
    ..the ubiquitously expressed protein tyrosine phosphatase PTP1B, suggesting that PTP1B may be a useful target for drug therapy in leptin resistance...
  18. Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
    Scott T Eblen; Fiscal Year: 2013
    Many ovarian tumors respond to initial drug therapy, but become refractory to drug treatment upon recurrence. Therefore, defining the mechanisms of drug resistance is important for existing and new cancer therapies...
  19. Oxymax System with Teadmill for Quantifying Exercise in Mice
    Neil B Ruderman; Fiscal Year: 2012
    ..of exercise performance in response to a wide variety of parameters including aging, genetic modifications and drug therapy. The PI, Dr...
  20. Jeffrey S Souris; Fiscal Year: 2016
    ..To overcome these deficiencies in current drug therapy and enable minimally invasive M-T staging of polyp/neoplastic disease in situ, we will synthesize and tri-..
  21. Bioengineering of Novel Synthetic Lipid-Peptide Lung Surfactants
    Robert H Notter; Fiscal Year: 2013
    ..to facilitate the delivery of exogenous DNA to animals with lung injury for future gene therapy or multi-drug therapy applications...
  22. Reactivation of Fetal Gamma-globin Genes for the Treatment of Beta-globin Disorde
    Osamu Tanabe; Fiscal Year: 2010
    ..Recent efforts in drug therapy for beta-thalassemia have also focused on stimulation of gamma-globin gene expression, but with only limited ..
  23. Peripheral T Cell tolerance by targeting AKT
    Claudio Anasetti; Fiscal Year: 2010
    ..To accomplish these objectives, our team has expertise in immunology, bone marrow transplantation and drug therapy. Unique transgenic, knock-out and knock-in mice are available for all the planned experiments...
  24. Tousled kinase contributes to survival of salivary acinar cells against radiation
    Gulshan Sunavala-Dossabhoy; Fiscal Year: 2013
    ..Future research can then be directed at determining whether a combination of protein and drug therapy will be more efficacious than either treatment alone...
  25. ERICA LYNN CAIN; Fiscal Year: 2014
    ..This synthetic lethal interaction has made PARPi an attractive drug therapy for BRCA2-deficient cancers of the breast, prostate, and ovary;however, PARPi resistance arises from the ..
  26. Therapeutic Value of Fish Oil Rx on SLE and Bone Loss in Mice
    GABRIEL J J FERNANDES; Fiscal Year: 2012
    ..the interaction of OMACOR n-3 fatty acids along with immunosuppressive cyclophosphamide and methylprednisolone drug therapy after the onset of SLE in controlling renal disease and bone loss in MRL/lpr mice...
  27. Rakesh C Kukreja; Fiscal Year: 2016
    ..The current lines of drug therapy are insufficient to control this devastating disease and its serious cardiovascular complications...
  28. Development of the orally delivered, non-absorbable ACE inhibitor enalaprilat for
    ELKE LIPKA; Fiscal Year: 2010
    ..The goal of this proposal is to develop an entirely new type of drug therapy for IBD using an existing, proven safe therapeutic, and focusing on local control of the inflammatory response, ..
  29. Targeted cell therapy for the treatment of ventricular tachycardia
    KENNETH LAURITA; Fiscal Year: 2010
    ..Current treatment with implantable cardioverter defibrillators, antiarrhythmic drug therapy, and radio frequency catheter ablation are ineffective at treating the underlying pathophysiological causes of ..
  30. Biology of Aerobic Capacity and Insulin Resistance
    Charles F Burant; Fiscal Year: 2012
    ..The information obtained will be used to design more effective diet, exercise or drug therapy that will prevent the illnesses associated with obesity.
  31. Suman Jayadev; Fiscal Year: 2016
    ..efforts, we have been less than successful to curb either the progression or initiation of AD through drug therapy. To do so, we need a stronger understanding of the fundamental elements of AD pathobiology...
  32. Synthesis of bone-selective osteogenic oxysterols
    Frank Stappenbeck; Fiscal Year: 2013
    ..Since the 1960's, bisphosphonate drug therapy has produced clinical benefits such as improved bone density and reduced fracture risk by slowing osteoclastic ..
  33. Flavin-Containing Monooxygenase in Lung
    David E Williams; Fiscal Year: 2013
    ..significant with the potential for high impact: it will lead to better matching of individuals with appropriate drug therapy. Relevance to Public Health: The WHO has termed TB a global health emergency...
  34. A short course: An organ systems approach to target the Metabolic syndrome
    Owen P McGuinness; Fiscal Year: 2012
    ..recognized for its excellence in translational research that uses bench to bedside research to improve drug therapy for human disease...
  35. CD8+ T Cell Immunity to Cytomegalovirus
    Stanley R Riddell; Fiscal Year: 2013
    ..Antiviral drug therapy with ganciclovir has reduced the incidence of early CMV disease in transplant recipients but causes ..
  36. Studies toward the development of monoamine oxidase B specific inhibitors
    ERIKA MARIE MILCZEK; Fiscal Year: 2010
    ..This finding is of particular interest due to the development of selective inhibitors for MAO B as a target for drug therapy for prevention of neurodegenerative disorders...
  37. RICHARD ARTHUR CHOLE; Fiscal Year: 2014
    ..An understanding of the pathogenicity and virulence of PA in cholesteatoma may lead to new targets of drug therapy or treatment modalities that will prevent or ameliorate the hearing loss associated with this disease...
  38. Metabolism and toxicity of NRTIs in non-replicating tissues
    Edward E McKee; Fiscal Year: 2013
    ..pathways will be measured by RT-PCR to capture changes in gene expression that may be caused by long-term drug therapy. Further, microarray and proteomic analysis will be included to correlate with the RT-PCR results and to ..
  39. Thomas A Kocarek; Fiscal Year: 2014
    ..Anti-cholesterol drug therapy, using statins, is now a proven approach for reducing the risk of developing coronary heart disease, and since ..
  40. Damon Hyde; Fiscal Year: 2015
    ..would allow far more patients to be comprehensively screened for surgical potential, both after conventional drug therapy has failed and early in the progression of the disease, before epileptic networks have developed which may ..
  41. Matthew R Hayes; Fiscal Year: 2016
    ..In addition, results may help identify potential targets for combination drug therapy to enhance the food intake and body weight suppressive effects of GLP-1- based pharmaceuticals.
  42. Allen T Bishop; Fiscal Year: 2016
    ..effectiveness of a surgically-created host-derived neoangiogenic circulation to maintain blood flow and function in living musculoskeletal tissue transplants without need for prolonged postoperative drug therapy or tolerance induction.
  43. Hypothalamic Mechanisms in Cachexia
    Daniel L Marks; Fiscal Year: 2013
    ..Attempts at drug therapy for cachexia with a variety of agents have met with limited success...
  44. Deciphering the Usher I protein interactome using a genetic approach
    Qing Y Zheng; Fiscal Year: 2013
    ..deafness model (for Usher 1 syndrome and presbycusis) that provides an ideal window of time for evaluating drug therapy;2) identify key molecules and mechanisms that lead to hair cell death and hearing loss in the models for the ..
  45. Barbara J Drew; Fiscal Year: 2015
    ..6 Despite routine immunosuppressant drug therapy, acute rejection is common, especially within the first 6 7 months following transplant surgery...
  46. c-Src/EGF Receptors Interactions and Therapeutic Resistance in Breast Cancer
    Sarah J Parsons; Fiscal Year: 2010
    ..novel signaling pathway emanating from the epidermal growth factor receptor (EGFR) that mediates resistance to drug therapy and to identify the downstream targets of this pathway...
  47. YVONNE SARAH LIN; Fiscal Year: 2014
    ..While genetic testing for CYP2D6 is becoming more accessible, guiding drug therapy with genetic information alone may not be sufficient in children as the genotype-phenotype relationship may be ..
  48. Molecular mechanisms of central chemoreception in breathing
    Marco Martina; Fiscal Year: 2013
    ..These experiments will shed light on one central question of animal physiology and may suggest new pharmacological targets for drug therapy.
  49. Engineering a packaging nanomotor for delivery of RNA and other molecules
    Venigalla B Rao; Fiscal Year: 2010
    ..This project will provide proof of principle data for the development of this system into a versatile delivery vehicle, delivering DNA, RNA, peptide, or drug therapy into the cell.
  50. Lentiviral-MGMT gene transfer into hematopoietic stem cells
    Stanton L Gerson; Fiscal Year: 2011
    ..can be transduced with a vector containing MGMT and selected for in vivo by administration of a DNA damaging drug therapy, i.e...
  51. DENNIS EDWARD OHMAN; Fiscal Year: 2016
    ..This can occur as a complication of emphysema, chronic bronchitis, cancer and immunosuppressive drug therapy. Exposure to this ubiquitous bacterium can result in nosocomial infections, which is common via respiratory ..
  52. Integrative Genomics of Vanin Gene Expression in Relation to CVD Risk
    Eric Moses; Fiscal Year: 2013
    ..The knowledge gained may lead to better methods for identifying those at greatest risk of CVD and point to new strategies for drug therapy.
  53. Modifying Lifestyle in Prehypertensive Older Rural Women
    CAROL HALL PULLEN; Fiscal Year: 2010
    ..Prehypertensive women are not candidates for drug therapy, but for lifestyle modifications to prevent progression to HTN and CVD...
  54. Overcoming Membrane Transporters to Improve CNS Drug Therapy
    Robert S B Clark; Fiscal Year: 2013
    ....
  55. EIAV Envelope Variation and Vaccine Efficacy
    Ronald C Montelaro; Fiscal Year: 2013
    ..Recent advances in multiple drug therapy for HIV-1 infected patients have certainly improved the length and quality of life for patients in economically ..
  56. Dynamic ICG and FA Software
    Timothy Holmes; Fiscal Year: 2009
    ..The Phase I objective is to show that it is feasible to detect a response to drug therapy. If time permits, other applications will be shown to be feasible during Phase I as well...
  57. Qiumin Tan; Fiscal Year: 2015
    ..In the hope of eventually developing combination drug therapy, which might be more effective and less toxic, I will seek additional ATXN1-modulating pathways in Aim 2...
  58. Prevention of oxidative stress decreases persistence of drug tolerant M. Tubercu
    Randall J Basaraba; Fiscal Year: 2010
    ..transcription factor nuclear redox factor2 (Nrf2) in Mtb-infected guinea pigs, conventional anti-tuberculosis drug therapy will be more effective against persistent, drug-tolerant bacilli...
  59. Randall J Basaraba; Fiscal Year: 2016
    ..This strategy could significantly improve the efficacy of current TB drug therapy by more rapidly eradicating, persistent, drug-tolerant bacilli...
  60. Diet, Activity, and Lifestyle as a Risk Factor for Colorectal Cancer
    Martha L Slattery; Fiscal Year: 2012
    ..Identification of polymorphisms or haplotypes that are relevant to colorectal cancer will advance our understanding of etiology, may lead to specific health recommendations, and can identify targets for drug therapy.
  61. 2012 Neurofibromatosis (NF) Conference
    Brigitte Widemann; Fiscal Year: 2012
    ..advances made in NF research in recent years and, particularly, recent advances into clinical trials and drug therapy development...
  62. Genes in Human Brain Ischemia
    W Andrew Kofke; Fiscal Year: 2011
    ..is the third leading cause of death and leading cause of disability in the United States, the impact of this research may be very significant, possibly leading to gene or new drug therapy of stroke or other brain ischemia syndromes.
  63. Julie A Johnson; Fiscal Year: 2014
    ..cardiovascular outcomes like heart attack and stroke for two commonly used drug classes, p-blockers and thiazide diuretics In the future genetic information might be used to guide selection of drug therapy for individual patients.
  64. Rapid High-Resolution Electroanatomical Cardiac Mapping System for the Treatment
    DORON HARLEV; Fiscal Year: 2009
    ..3 million Americans and ~5.6 million by 2050. Traditional treatment modalities, namely drug therapy and open heart surgery, have been found to be inadequate for a growing number of patients, either because of ..
  65. DEVELOPMENT OF A DRUG THERAPY TO AMELIORATE PERMANENT HEARING LOSS
    Jianxin Bao; Fiscal Year: 2010
    ..This proposal will discover new drug combinations to prevent NIHL, and if successful, provide sufficient animal data for future clinical trials to prevent permanent NIHL. ..
  66. M. AVIUM DISEASE--INHALED LIPOSOME ANTI-TB DRUG THERAPY
    Hans Schreier; Fiscal Year: 1992
    M. AVIUM DISEASE: INHALED LIPOSOME ANTI-TB DRUG THERAPY. Of the atypical mycobacteria, the Mycobacterium avium-intracellular complex (MAIC) is the most common human pathogen...
  67. Developing an inactivated whole cell H. pylori vaccine
    GARY NABORS; Fiscal Year: 2006
    ..exists no vaccine for the prevention of infection with the ubiquitous gastric pathogen Helicobacter pylori, and drug therapy for the infection is complicated by poor patient compliance, the high cost of treatment, and ineffectiveness ..
  68. Novel 3D Catheter Tracking System for Intracardiac Navigation
    DORON HARLEV; Fiscal Year: 2009
    ..Traditional treatment modalities, namely drug therapy and open heart surgery, have been found to be inadequate for a growing number of patients, either because of ..
  69. CHOLESTEROL TREATMENT MODEL FOR LOW INCOME PATIENTS
    Ross Simpson; Fiscal Year: 1993
    ..will use a standardized screening protocol, but control group providers will receive no assistance with diet or drug therapy. We have designed and are currently pilot testing the provider-directed diet treatment component of the Assist ..
  70. Quantitative MRI-based Assessment of Aerosol Deposition in the Lung
    Chantal Darquenne; Fiscal Year: 2009
    ..to airborne particulate matter (PM) and infectious agents as well as in assessing the efficacy of inhaled drug therapy. Detailed yet non-invasive studies of peripheral aerosol deposition (DE) are almost impossible in humans...
  71. Race and Long-Term Diabetes Self-Management in an HMO
    Dennis Ross Degnan; Fiscal Year: 2004
    ..relationships between race, diabetes self-management (including self-monitoring of blood glucose and diabetes drug therapy), glycemic control, and diabetes complications in a managed care setting over a nine-year period...
  72. Metabolomics Network for Drug Response Phenotype
    RIMA F KADDURAH DAOUK; Fiscal Year: 2010
    ..could lead to more effective approaches for preventing and treating CVD and could result in "personalized" drug therapy. We propose a partnership between the Metabolomics Network for Drug Response Phenotype and two centers of ..
  73. Population-Specific Genetic Determinants of Susceptibility to Chemotherapies
    PETER HUGH O apos DONNELL; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The paradigm of individualized drug therapy based on an individual's unique genetic make-up is especially desirable in the field of hematology/oncology, where the therapeutic index is often ..
  74. ZIDOVUDINE METABOLISM: REBRETRON TREATED HUMAN PATIENTS
    Jose Rodriguez; Fiscal Year: 2003
    ..Thus, in the dTTP/ZDV-TP ratio increases dramatically, we might be changing from a three-drug therapy in HAART (ZDV + two other drugs including a protease inhibitor) to a two-drug therapy (two other drugs ..
  75. Novel Modulators of LDL Metabolism
    Nabil Elshourbagy; Fiscal Year: 2009
    ..familial hypercholesterolemia who have markedly elevated cholesterol levels respond poorly to current drug therapy, and are at high risk of premature cardiovascular disease...
  76. Electropulsation mediated drug therapy for Onychomycosis
    SATHYANARAYANA MURTHY; Fiscal Year: 2009
    ....
  77. Clinical trial of chloroquine combinations in Malawi
    CHRISTOPHER PLOWE; Fiscal Year: 2009
    Combination drug therapy for malaria, especially artemisinin-based combination therapy (ACT), is intended to deter resistance by rapidly eliminating malaria parasites using drugs with different mechanisms...